Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients:the R4-RA RCT

Humby, Frances; Durez, Patrick; Buch, Maya H; Lewis, Myles J; Bombardieri, Michele; John, Christopher; Rizvi, Hasan; Warren, Louise; Peel, Joanna; Fossati-Jimack, Liliane; Hands, Rebecca E; Giorli, Giovanni; Rivellese, Felice; Cañete, Juan D; Taylor, Peter C; Sasieni, Peter; Fonseca, João E; Choy, Ernest; Pitzalis, Costantino

doi:10.3310/GOPL1729

Graphic version of this page | Change how these pages look

Journals Library

NHS NIHR - National Institute for Health and Care Research

Journals

Twitter
Facebook
LinkedIn
Email

An error occurred retrieving content to display, please try again.

Home >> Journals >> Efficacy and Mechanism Evaluation >> Page Not Found

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Home >> Journals >> Efficacy and Mechanism Evaluation >> Volume {{metadata.Volume}} >> Issue {{metadata .Issue }}
Extended Research Article
i

Toolkit

View Award

This trial did not show that tocilizumab was more effective than rituximab in patients with a B-cell-poor pathotype in the primary analysis; however, superiority was shown in most supplementary and secondary analyses using a molecular classification.

Detailed Author information
Detailed Author information

Frances Humby ¹, Patrick Durez ², Maya H Buch ³, Myles J Lewis ¹, Michele Bombardieri ¹, Christopher John ¹, Hasan Rizvi ⁴, Louise Warren ¹, Joanna Peel ¹, Liliane Fossati-Jimack ¹, Rebecca E Hands ¹, Giovanni Giorli ¹, Felice Rivellese ¹, Juan D Cañete ⁵, Peter C Taylor ⁶, Peter Sasieni ⁷, João E Fonseca ⁸, Ernest Choy ⁹, Costantino Pitzalis ^1,^*

¹ Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, UK
² Institute of Experimental and Clinical Research, Université Catholique de Louvain, Louvain, Belgium
³ Clinical Trials Research Unit, University of Leeds, Leeds, UK
⁴ Blizard Institute, Barts Health NHS Trust, London, UK
⁵ Arthritis Unit, L’Institut d’Investigacions Biomèdiques, Barcelona, Spain
⁶ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
⁷ King’s Clinical Trial Unit, King’s College London, London, UK
⁸ Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal
⁹ Section of Rheumatology, Cardiff University School of Medicine, Cardiff University, Cardiff, UK
^* Corresponding author Email: c.pitzalis@qmul.ac.uk

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

[Image - Crossmark status check]

Report Content

Full Report
Abstract
Plain English Summary
Plain Language Summary
Scientific Summary

The full text of this issue is available as a PDF document from the Toolkit section on this page.

Responses to this report

No responses have been published.

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors. Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

Enter response message*
Name (title, first name, last name)*
Occupation / Job title*
Affiliation / Employer*
Email*
Other authors
For example, if you are responding as a team or group. Please ensure you include full names and separate these using commas
Statement of competing interestsWe believe that readers should be aware of any competing interests (conflicts of interest).The International Committee of Medical Journal Editors (ICMJE) define competing interests as including: financial relationships with industry (for example through employment, consultancies, stock, ownership, honoraria, and expert testimony), either directly or through immediate family; personal relationships; academic competition; and intellectual passion.
If yes, please provide details below
Enter response title*
Enter CAPTCHA What is six multiplied by three?*

By submitting your response, you are stating that you agree to the terms & conditions